Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus

다국어 초록 (Multilingual Abstract)

Background: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. While studies conducted in other countries have indicated the efficacy and safety of using sitagliptin to treat type 2 diabetes mellitus (T2DM), its predictors of effects to sitagliptin are not well understood. Therefore, we evaluated the predictive clinical parameters for the therapeutic benefits of sitagliptin when added to an ongoing metformin or sulfonylurea therapy in Korean T2DM subjects.
Methods: We obtained data from 251 Korean T2DM subjects who had recently started taking sitagliptin as add-on therapy. Exclusion criteria included any insulin use. Changes in HbA1c (ΔHbA1c) and fasting plasma glucose (ΔFPG) were assessed by comparing baseline levels prior to sitagliptin administration to levels 12 and 24 weeks after treatment. Responders were defined as subjects who experienced decrease from baseline of >10% in ΔHbA1c or >20% in ΔFPG levels at 24 weeks.
Results: We classified 81% of the subjects (204 out of 251) as responders. The responder group had a lower mean body mass index (23.70±2.40 vs. 26.00±2.26, P≤0.01) and were younger (58.83±11.57 years vs. 62.87±12.09 years, P=0.03) than the non-responder group.
Conclusion: In Korean T2DM subjects, sitagliptin responders had lower body mass index and were younger compared to non-responders.

참고문헌 (Reference)

1 이찬희, "한국 성인에서 제2형 당뇨병의 예측인자로서 공복 혈장 혈당과 당화혈색소의 조합" 대한당뇨병학회 33 (33): 306-314, 2009

2 김재현, "인크레틴을 기초로 한 제2형 당뇨병의 복합약물요법" 대한의사협회 52 (52): 1030-1036, 2009

3 임수, "국내 3차 의료기관의 당뇨병 조절 상태 및 합병증 보고 - 2006∼2007 대한당뇨병학회 역학소위원회 -" 대한당뇨병학회 33 (33): 48-57, 2009

4 The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus" 329 : 977-986, 1993

5 Choi SH, "Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus" 69 : 549-555, 2008

6 Nauck MA, "Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial" 9 : 194-205, 2007

7 Raz I, "Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus" 49 : 2564-2571, 2006

8 Aschner P, "Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes" 29 : 2632-2637, 2006

9 Charbonnel B, "Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone" 29 : 2638-2643, 2006

10 Rosenstock J, "Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel- group study" 28 : 1556-1568, 2006

11 Hemkens LG, "Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study" 52 : 1732-1744, 2009

12 Yoon KH, "Quantification of the pancreatic beta-cell mass in normal and type 2 diabetic subjects in Korea" 24 : 524-532, 2000

13 Ehninger G, "Putting insulin glargine and malignancies into perspective" 14 : 1169-1174, 2009

14 Bonora E, "Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence" 44 : 2107-2114, 2001

15 Dejgaard A, "No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis" 52 : 2507-2512, 2009

16 UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" 352 : 837-853, 1998

17 Ristic S, "Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response" 7 : 692-698, 2005

18 Riche DM, "Impact of sitagliptin on markers of beta-cell function: a meta-analysis" 337 : 321-328, 2009

19 The Diabetes Control and Complications Trial (DCCT) Research Group, "Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial" 75 : 894-903, 1995

20 Mu J, "Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes" 55 : 1695-1704, 2006

21 Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study" 321 : 405-412, 2000